NASDAQ
4.11USD
-0.04 (-0.96%)
We have scored 52 news catalysts on ARS Pharmaceuticals, Inc. (SPRY) over the past 12 months. The biggest single-day move next to one of them came Mar 29, 2026, when SPRY closed −5.7%: “Grabar Law Office Investigates Claims on Behalf of Long-term Shareholders of Super Micro Computer, Inc. (SMCI)”. Coverage across the window leans negative (average ticker sentiment −0.68). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
408.1M
P/E
—
EPS
—
Beta
0.88
52W range
4.1-13.15
Day range
4.10–4.20
Open
4.14
Prev close
4.15
Volume
1.9M
Avg volume
1.9M
Dividend
0.00
IPO
2020-12-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ARS Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SPRY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
